OBJECTIVE To evaluate the efficacy， safety and cost-effectiveness of tirzepatide for diabetes mellitus type 2 （T2DM） and long-term weight management， and provide evidence-based basis for clinical drug treatment and health insurance policy formulation. METHODS Computer searches were conducted in Embase， PubMed， the Cochrane Library， CNKI and health technology assessment （HTA） official website from their inception to October 1st 2024 to collect HTA report， systematic review/ meta-analysis and pharmacoeconomic study on tirzepatide for the treatment of T2DM or for weight management. After data extraction and quality evaluation， descriptive analysis was performed on the research results. RESULTS Totally 18 papers were included， including 14 systematic reviews/meta-analyses and 4 pharmacoeconomics studies， and no HTA report was retrieved. In terms of efficacy， most results showed that the tirzepatide 10 mg and 15 mg were significantly better than other glucagon-like peptide-1 （GLP-1） receptor agonists in reducing glycosylated hemoglobin， body weight， and waist circumference （P＜0.05）. In terms of safety， compared with other GLP-1 receptor agonists， tirzepatide did not increase the incidence of gastrointestinal-related adverse events （AE）， the incidence of AE of grade ≥3， or the incidence of severe hypoglycemia （P＞0.05）. However， tirzepatide 15 mg may significantly increased the incidence of hypoglycemia and the rate of discontinuation due to adverse reactions （P＜ 0.05）. In terms of cost-effectiveness， based on the background of foreign pharmacoeconomic studies， tirzepatide was more cost- effective compared to semaglutide and liraglutide in the treatment of T2DM or for weight management. CONCLUSIONS Tirzepatide at doses of 10 mg and 15 mg has good efficacy and safety for the treatment of T2DM and for long-term weight management. However， when using the 15 mg dose of tirzepatide， close monitoring is required due to the risk of hypoglycemia and discontinuation due to adverse reactions it may pose. Based on pharmacoeconomic studies conducted abroad results， tirzepatide exhibits economic advantages.

Background In the context of global climate change, investigating the impact of temperature variability (TV) on the circulatory system is of significant importance for public health promotion. Objective To evaluate the effect of TV on the risk of hospital admissions for circulatory system diseases in Tangshan City. Methods Data on hospital admissions for circulatory diseases from four general hospitals in Tangshan between 2021 and 2023 were collected, while concurrent meteorological data were also obtained. A time-stratified case-crossover design was employed to analyze the association between TV and the risk of hospital admissions for circulatory system diseases. Subgroup analyses were further conducted by gender, age, and cold/heat wave days. Results A total of 11974 hospital admissions for circulatory system diseases were recorded from 2021 to 2023, with a median daily temperature of 13.90 ℃. The effects of TV01 through TV07 on hospitalization risks for overall circulatory system diseases and coronary heart disease were all statistically significant (P<0.05). Additionally, the effects of TV01 and TV04 through TV07 on hospitalization risk for stroke were also statistically significant (P<0.05). A 1°C increase in TV07 was associated with odds ratios (ORs) of 1.041 (95%CI: 1.032, 1.050) for overall circulatory system diseases, 1.050 (95%CI: 1.037, 1.064) for coronary heart disease, and 1.029 (95%CI: 1.014, 1.045) for stroke. Furthermore, the effect of TV on the risk of hospital admissions were stronger during cold wave days compared with non-cold/hot wave days. Conclusion TV may contribute to increased risk of hospital admissions for circulatory system diseases in Tangshan, and the impact of TV exhibits a certain lag effect. It is suggested to explore and develop targeted intervention measures.